Clinical Research Directory

Inclusion Criteria: * Patient with initial diagnosis of multiple myeloma has just been established * Therapeutic indication and eligible for a HSC autograft (if the HSC autograft could not be performed, the patient will still be retained in the study). * Status ECOG 0, 1 or 2 * Age ≥ 18 and \< 75 ans years * Effective contraception for women * Informed consent signed * Patient able to lie flat for 30 minutes * Patient affiliated to a social security scheme Exclusion Criteria: * Patient diagnosed with a diagnosis of MGUS (Monoclonal Gammapathy of Undetermined Significance = monoclonal gammopathy of undetermined significance), indolent myeloma ("smoldering myeloma"), non-secreting myeloma or recurrent myeloma, * Patient already under treatment for myeloma. * Patient not eligible for intensive treatment followed by a HSC autograft. * Patient with concomitant neoplasia * Patient with a history of hematological or solid neoplasia, except if it is a basal cell carcinoma of the skin or an adenocarcinoma in situ of the uterine cervix. * Patient with a history of sarcoidosis * Uncontrolled diabetes. * Patient treated with long-term corticosteroids * Patient being treated with hematopoietic growth factors * Patient in sepsis. * Claustrophobic patient. * Refusal of patient consent. * Pregnant or lactating woman. * Women of childbearing potential without effective contraception. * Person deprived of liberty or under guardianship * Impossibility to submit to the medical follow-up of the trial for geographic, social or psychological reasons. * History of allergic reaction attributed to 18F-fluorodeoxyglucose or to 18F-fluorocholine.